

NanoEcho has been selected to participate in a business development program

NanoEcho has, as one of seven companies, been chosen to participate cost-free in the Smile Incubator and Medicon Village program "10 X Health." The program provides expertise in business development and focuses on established Life Science companies transitioning from being a startup to becoming a scale-up.

The objective of the "10 X Health" program is to maintain and strengthen innovation and networks within Life Science in southern Sweden. This is achieved by expanding the support from SmiLe Incubator and Medicon Village to include companies that have moved beyond the startup stage and are now in a more commercial phase. Through the program, participating companies gain access to experts in business development.

"Becoming selected for the '10 X Health' program is a fantastic opportunity for NanoEcho, something I am truly happy and proud about. I am looking forward to benefiting from the knowledge the program will provide and creating valuable contacts within the industry. It will be an important part of our journey towards becoming a profitable company," says Linda Persson, CFO of NanoEcho

"10 X Health" is a business development program focused on life science companies. The goal is to equip established companies with the skills needed to accelerate their development. The program lasts for 12 months and includes aspects such as entrepreneurship, financing, internationalisation, and effective leadership.

For further information, please contact:

Kristina Hallström, CMO & CCO

email: ir@nanoecho.se

NanoEcho develops a new technology for clearer diagnostics of, in the first indication, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern patented ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simple, and cost-effective diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalised treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se

Press Release 16 January 2024 09:40:00 CET

